

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.usrno.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/655,562	09/04/2003	Sharon L. Bishop-Hurley	UVMO:022US	5742
7590 04/11/2005			EXAMINER	
Steven L. Highlander			RUSSEL, JEFFREY E	
FULBRIGHT & JAWORSKI L.L.P. SUITE 2400			ART UNIT	PAPER NUMBER
600 CONGRESS AVENUE AUSTIN, TX 78701			1654	
			DATE MAILED: 04/11/2005	5

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
065 4-4' 0	10/655,562	BISHOP-HURLEY ET AL.				
Office Action Summary	Examiner	Art Unit				
	Jeffrey E. Russel	1654				
The MAILING DATE of this communication appeared for Reply	ears on the cover sheet with the co	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	6(a). In no event, however, may a reply be tim within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from to cause the application to become ABANDONED	ely filed will be considered timely. the mailing date of this communication. 0 (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 04 Se	eptember 2003.					
2a) This action is <b>FINAL</b> . 2b) This	This action is <b>FINAL</b> . 2b) This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) ⊠ Claim(s) <u>1-65</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) <u>1-65</u> are subject to restriction and/or e						
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Example 11.	, , , ,	` '				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priori	have been received. have been received in Application ty documents have been received (PCT Rule 17.2(a)).	on No d in this National Stage				
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary ( Paper No(s)/Mail Dat	e				
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal Pa	itent Application (PTO-152)				

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

 Claims 1-46, drawn to methods of using peptides to inhibit bacterial growth or infection, classified in class 514, subclass 14.

- II. Claims 50-55, drawn to a method of screening a phage library, classified in class435, subclass 32.
- III. Claims 58-65, drawn to a method of identifying a receptor with peptides, classified in class 436, subclass 501.

The inventions of Groups I, II, and III are patentably distinct from one another because of the materially different method steps and because of the materially different results of each method. Group I involves therapeutic treatments and sterilization procedures by which bacterial growth or infection is prevented, inhibited, and or treated. Group II involves a method of identifying peptides with anti-H. influenzae activity. Group III involves a method of identifying bacterial receptors.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and the search required for Group I is not required for Groups II or III, and the search required for Group II is not

Art Unit: 1654

required for Groups I or III, and the search required for Group III is not required for Groups I or II, restriction for examination purposes as indicated is proper.

If Applicants elect either the invention of Group I or the invention of Group III, linking claims 47-49, 56, and 57 will be examined with the elected invention. Claims 47-49, 56, and 57 link(s) inventions I and III. The restriction requirement between the linked inventions is subject to the nonallowance of the linking claim(s), claims 47-49, 56, and 57. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. In re Ziegler, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

2. If Applicants elect either the invention of Group I or the invention of Group III, the following restriction among the claimed amino acid sequences is additionally imposed:

Claims 1, 10-19, 28-49, and 56-65 are generic to a plurality of disclosed patentably distinct sequences comprising: SEQ ID NOS: 1, 2, 3, 4, 5, 6, 7, and 8. These sequences are patentably distinct, each from the other, because of their materially different amino acid sequences. Searching all of the claimed sequences would constitute an undue burden on the examiner because different sequence searches would be required for each of the claimed

Art Unit: 1654

sequences. Applicant is required under 35 U.S.C. 121 to elect a single disclosed sequence, even though this requirement is traversed. This restriction requirement among the claimed amino acid sequences applies to the linking claims as well as to the inventions of Groups I and III.

Should applicant traverse on the ground that the sequences are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the sequences to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

This is not a species election, but a holding that the sequences are patentably distinct, one from the other.

3. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey E. Russel at telephone number (571) 272-0969. The examiner can normally be reached on Monday-Thursday from 8:30 A.M. to 6:00 P.M. The examiner can also be reached on alternate Fridays.

Application/Control Number: 10/655,562

Art Unit: 1654

Page 5

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor Bruce Campell can be reached at (571) 272-0974. The fax number for formal communications to be entered into the record is (571) 273-8300; for informal communications such as proposed amendments, the fax number (571) 273-0969 can be used. The telephone number for the Technology Center 1600 receptionist is (571) 272-1600.

Jeffrey E. Russel

Primary Patent Examiner

Art Unit 1654

**JRussel** 

April 5, 2005